Expansion of KRAS Cancer Program with MEK Inhibitor

Boehringer Ingelheim Expands KRAS Cancer Program with Lupin ’s Clinical Stage MEK Inhibitor CompoundBoehringer Ingelheim strengthens its pipeline portfolio for patients with gastrointestinal and lung cancers with this new licensing, development and commercialization agreementLupin ’s proprietary MEK inhibitor compound is planned for clinical development in combination with Boehringer Ingelheim’s emerging KRAS inhibitor pipeline to address KRAS-driven cancersLupin to receive a $20 million upfront payment with potential total milestones of more than $700 million and royalties on the sales of the product
Source: Boehringer Ingelheim Corporate News - Category: Research Source Type: news